Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin G Sanda

Showing results (141-150 of 180) with videos related to

Pageof 18
Sort By:
Clinical Genitourinary Cancer|April 26, 2026
Utilization, Cost, and Subsequent Salvage Treatment of Ablative Therapies for Localized Prostate Cancer in the United StatesNikhil T Sebastian, Dattatraya Patil, Pretesh R Patel, et al.
The Journal of Urology|January 15, 2018
Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part II: Recommended Approaches and Details of Specific Care OptionsMartin G Sanda, Jeffrey A Cadeddu, Erin Kirkby, et al.
The Journal of Urology|December 6, 2017
Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part I: Risk Stratification, Shared Decision Making, and Care OptionsMartin G Sanda, Jeffrey A Cadeddu, Erin Kirkby, et al.
Cancer|February 26, 2013
Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancerPhillip J Gray, Jonathan J Paly, Beow Y Yeap, et al.
Cancer|January 3, 2014
Comparative effectiveness study of patient-reported outcomes after proton therapy or intensity-modulated radiotherapy for prostate cancerBradford S Hoppe, Jeff M Michalski, Nancy P Mendenhall, et al.
The Journal of Urology|July 27, 2011
Expanded prostate cancer index composite for clinical practice: development and validation of a practical health related quality of life instrument for use in the routine clinical care of patients with prostate cancerPeter Chang, Konrad M Szymanski, Rodney L Dunn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 9, 2009
Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United StatesJuan-Miguel Mosquera, Rohit Mehra, Meredith M Regan, et al.
The Journal of Urology|July 30, 2017
Decision Support with the Personal Patient Profile-Prostate: A Multicenter Randomized TrialDonna L Berry, Fangxin Hong, Traci M Blonquist, et al.
Urologic Oncology|December 23, 2020
Decision regret, adverse outcomes, and treatment choice in men with localized prostate cancer: Results from a multi-site randomized trialDonna L Berry, Fangxin Hong, Traci M Blonquist, et al.
JU Open Plus|February 19, 2026
Combining Serum Prostate Health Index With Urinary PCA3 and TMPRSS2:ERG RNA Testing Improves Detection of Clinically Significant Prostate CancerNicholas W Eyrich, Yijian Huang, Yingye Zheng, et al.
Pageof 18

Showing results (141-150 of 180) with videos related to

Sort By:
Pageof 18
Clinical Genitourinary Cancer|April 26, 2026
Utilization, Cost, and Subsequent Salvage Treatment of Ablative Therapies for Localized Prostate Cancer in the United StatesNikhil T Sebastian, Dattatraya Patil, Pretesh R Patel, et al.
The Journal of Urology|January 15, 2018
Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part II: Recommended Approaches and Details of Specific Care OptionsMartin G Sanda, Jeffrey A Cadeddu, Erin Kirkby, et al.
The Journal of Urology|December 6, 2017
Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part I: Risk Stratification, Shared Decision Making, and Care OptionsMartin G Sanda, Jeffrey A Cadeddu, Erin Kirkby, et al.
Cancer|February 26, 2013
Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancerPhillip J Gray, Jonathan J Paly, Beow Y Yeap, et al.
Cancer|January 3, 2014
Comparative effectiveness study of patient-reported outcomes after proton therapy or intensity-modulated radiotherapy for prostate cancerBradford S Hoppe, Jeff M Michalski, Nancy P Mendenhall, et al.
The Journal of Urology|July 27, 2011
Expanded prostate cancer index composite for clinical practice: development and validation of a practical health related quality of life instrument for use in the routine clinical care of patients with prostate cancerPeter Chang, Konrad M Szymanski, Rodney L Dunn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 9, 2009
Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United StatesJuan-Miguel Mosquera, Rohit Mehra, Meredith M Regan, et al.
The Journal of Urology|July 30, 2017
Decision Support with the Personal Patient Profile-Prostate: A Multicenter Randomized TrialDonna L Berry, Fangxin Hong, Traci M Blonquist, et al.
Urologic Oncology|December 23, 2020
Decision regret, adverse outcomes, and treatment choice in men with localized prostate cancer: Results from a multi-site randomized trialDonna L Berry, Fangxin Hong, Traci M Blonquist, et al.
JU Open Plus|February 19, 2026
Combining Serum Prostate Health Index With Urinary PCA3 and TMPRSS2:ERG RNA Testing Improves Detection of Clinically Significant Prostate CancerNicholas W Eyrich, Yijian Huang, Yingye Zheng, et al.
Pageof 18